

Protein kinase C activation enhances morphine-induced  
rapid desensitization of  $\mu$ -opioid receptors in mature rat  
locus coeruleus neurons

Christopher P. Bailey, Eamonn Kelly and Graeme  
Henderson

Department of Pharmacology  
University of Bristol  
School of Medical Sciences  
University Walk  
Bristol BS8 1TD  
United Kingdom

**Running title:**

PKC enhances morphine desensitization of  $\mu$ -opioid receptors

**Author for correspondence:**

Dr. Chris Bailey, Department of Pharmacology, University of Bristol, University  
Walk, Bristol, BS8 1TD, United Kingdom

Tel: 44-0117-928-8872

Fax: 44-0117-925-0168

E-mail: Chris.Bailey@bris.ac.uk

<b>Number of text pages:</b>	31
<b>Number of figures:</b>	4
<b>Number of references:</b>	47
<b>Number of words in abstract:</b>	186
<b>Number of words in introduction:</b>	497
<b>Number of words in discussion:</b>	1480

**Abbreviations**

GF109203x: 2-[1-(3-Dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-  
maleimide

GIRK: G-protein-coupled inwardly rectifying K<sup>+</sup> channel

GRK: G-protein coupled receptor kinase

PMA: phorbol-12-myristate-13-acetate

## ABSTRACT

Recent studies have shown that morphine, in contrast to other agonists at the  $\mu$ -opioid receptor, causes very little rapid  $\mu$ -opioid receptor desensitization or internalization in adult rat mammalian neurons raising important questions about how morphine tolerance is induced. Here we show that morphine can indeed cause marked rapid desensitization of  $\mu$ -opioid receptors in mature rat locus coeruleus neurons when protein kinase C is also activated. Thus, activation of Gq-coupled  $M_3$  muscarinic receptors or application of a phorbol ester enhanced the desensitization of the  $\mu$ -opioid receptor-evoked potassium current in rat locus coeruleus neurons. The enhancement of desensitization was reversible by the protein kinase C inhibitors chelerythrine and GF109203X and resulted from an effect at the level of the  $\mu$ -opioid receptor rather than the potassium channel. This is the first finding that morphine can induce rapid MOR desensitization in adult rat neurons, and as reduced protein kinase C activity *in vivo* attenuates morphine tolerance, we propose that G-protein coupled receptor crosstalk and the level of protein kinase C activity may play critical roles in the desensitization of the  $\mu$ -opioid receptor and could underlie the development of morphine tolerance.

The rewarding and analgesic effects of morphine occur through activation of  $\mu$ -opioid receptors (MORs; Matthes et al., 1996). In the whole animal, tolerance to morphine develops rapidly, even after a single dose (Inoue and Ueda, 2000), compromising the clinical efficacy of morphine, as well as contributing to the social problems inherent in recreational opioid abuse. Much effort has been spent trying to uncover the cellular mechanisms underlying the development of morphine tolerance, but they remain poorly understood. It had long been held that tolerance to morphine occurs, at least in part, by MOR desensitization (Nestler and Aghajanian, 1997). Recently, however, studies examining rapid MOR desensitization and internalization by morphine has cast doubt over these processes contributing to morphine tolerance, as it has recently been observed that morphine, in direct contrast to other agonists, causes very little rapid MOR desensitization or internalization in adult rat locus coeruleus (LC) neurons or HEK293 cells (Whistler et al., 1999; Finn and Whistler, 2001; Alvarez et al., 2002; Bailey et al., 2003). This finding has resulted in a re-examination of the fundamental assumptions concerning opioid action and how tolerance to morphine occurs (Whistler et al., 1999; Finn and Whistler, 2001). It was speculated (Finn and Whistler, 2001) that morphine produces tolerance because it does not induce rapid receptor desensitization but continues to activate the receptors and thus evokes other adaptive mechanisms that result in the development of tolerance.

In the present study, we have examined the role of protein kinase C (PKC) in morphine-induced desensitization of native MORs in mature mammalian LC neurons, at the single neuron level. LC neurons have been studied because they are a homogeneous population of neurons that express the MOR in the absence of other

opioid receptor types (North et al., 1987). We observed that concomitant PKC activation through either M<sub>3</sub> muscarinic receptor activation or by exposure to a phorbol ester resulted in a marked increase in the amount of MOR desensitization induced by morphine and enhanced MOR desensitization induced by the endogenous opioid peptide, Met-enkephalin (ME). At present it is unclear how PKC enhances morphine-induced desensitization. This could be by direct phosphorylation of the MOR or by activation and potentiation of other cellular mechanisms involved in G-protein-coupled receptor desensitization such as G-protein coupled receptor kinases (GRKs), arrestins and MAP kinases, which could also lead to an increase in MOR desensitization (Liu and Anand, 2001).

A number of previous *in vivo* studies have shown that reduced PKC activity attenuates morphine tolerance (e.g., Watkins et al., 1984; Trujillo and Akil, 1991; Inoue and Ueda, 2000; Granados-Soto et al., 2000; Popik et al., 2000; Zeitz et al., 2001; Bohn et al., 2002; Hua et al., 2002; Powell et al., 2003). This study constitutes the first observation of morphine causing significant rapid MOR desensitization in mature rat neurons, and highlights the crucial requirement for PKC in this phenomenon. We therefore propose that morphine-induced MOR desensitization may contribute to morphine tolerance, and that PKC plays a crucial role in this process.

## MATERIALS AND METHODS

### Brain Slice Preparation

Male Wistar rats (130-170g) were killed by cervical dislocation, the brains removed and rapidly submerged in ice-cold cutting solution containing (mM) 20 NaCl, 2.5 KCl, 0.5 CaCl<sub>2</sub>, 7 MgCl<sub>2</sub>, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 85 sucrose, 25 D-glucose, 60 NaHCO<sub>3</sub>; saturated with 95% O<sub>2</sub>/5% CO<sub>2</sub>. Horizontal slices (250µm thick) containing the LC were prepared using a vibratome (Agar Scientific, UK; Fiorillo and Williams, 1996). Immediately upon cutting, slices were submerged in an artificial cerebrospinal fluid (aCSF) containing (mM) 126 NaCl, 2.5 KCl, 1.2 MgCl<sub>2</sub>, 2.4 CaCl<sub>2</sub>, 1.2 NaH<sub>2</sub>PO<sub>4</sub>, 11.1 D-glucose, 21.4 NaHCO<sub>3</sub>, 0.1 ascorbic acid; saturated with 95% O<sub>2</sub>/5% CO<sub>2</sub> at 34°C, and were left to equilibrate for at least 1 h. All experiments were performed in accordance with the U.K. Animals (Scientific Procedures) Act 1986, the European Communities Council Directive 1986 (86/609/EEC) and the University of Bristol ethical review document.

### Whole-cell patch-clamp recordings

Slices were submerged in a slice chamber (0.5 ml) mounted on the microscope stage and superfused (2.5-3 ml.min<sup>-1</sup>) with aCSF at 33-34°C. LC neurons were visualized by Nomarski optics and individual cell somata were cleaned by gentle flow of aCSF from a pipette. Whole-cell voltage-clamp recordings ( $V_h = -60$  mV) were made using electrodes (3-6 MΩ) filled with (mM) 115 K-gluconate, 10 HEPES, 11 EGTA, 2 MgCl<sub>2</sub>, 10 NaCl, 2 MgATP, 0.25 Na<sub>2</sub>GTP (pH 7.3, osmolarity 270 mOsm). Recordings of whole cell current were filtered at 2kHz using an Axopatch 200B amplifier (Axon Instruments, USA) and analysed off-line using pClamp (Axon

Instruments, USA). All drugs were applied in the superfusing solution in known concentrations. Naloxone (1  $\mu$ M) was applied at the end of each morphine application to antagonize the response completely, ME was allowed to wash out. In those experiments in which  $\alpha_2$  adrenoceptor desensitization was studied, noradrenaline (NA) was applied in the presence of prazosin (1  $\mu$ M) and cocaine (3  $\mu$ M). Desensitization of evoked currents was quantified by expressing the magnitude of decline in current, as a percentage of the initial peak current. Cells in which the maximum opioid-evoked currents were < 50 pA were excluded from the data analysis.

### **Statistical analysis**

All data are presented as mean  $\pm$  standard error of the mean. Two-way ANOVA was used for statistical analysis of desensitization of opioid-induced currents. Student's t-test was used for analysis of lines of best-fit of desensitization kinetics.

## RESULTS

### **Activation of PKC by a phorbol ester enhances morphine desensitization**

Activation of MORs on LC neurons evoked a transmembrane current due to the opening of G-protein-coupled inwardly rectifying K<sup>+</sup> channels (GIRKs), and by performing whole-cell patch-clamp recordings, a real-time index of MOR activation could be recorded. When a receptor-saturating concentration of morphine (30 μM) was applied, an outward current ( $122 \pm 7$  pA; n = 12) was rapidly induced and over the course of a 7 min drug application, only a small degree of desensitization occurred (Fig. 1a,c,g). In contrast, ME, applied at the receptor-saturating concentration of 30 μM evoked an outward current (peak current  $232 \pm 18$  pA; n = 14) that desensitized rapidly in the continued presence of the drug (Fig. 1e,f,g). This desensitization did not involve PKC as it was not inhibited by chelerythrine (5 μM; Fig. 1h-i).

PKC can be directly activated by phorbol esters. Fig. 1b-d show that in slices pre-incubated for 20 min with phorbol-12-myristate-13-acetate (PMA; 1 μM), morphine-induced desensitization was dramatically increased. The effect of PMA was blocked by the PKC inhibitor, chelerythrine (5 μM; Fig. 1d).

PMA treatment also increased ME-induced desensitization. Pre-incubation with PMA (1 μM; 20 min) increased ME-induced desensitization (Fig. 1e-f), an effect that was blocked by chelerythrine (5 μM; Fig. 1f). The apparent increased 'noise' level in the presence of PMA (see current traces in Fig. 1) is due to the increased frequency



of spontaneous EPSCs and IPSCs produced by PMA. This has previously been reported to occur at other CNS synapses (Malenka et al., 1986).

All desensitization traces could be fitted well to single exponential decays (Fig. 1g;  $R^2 > 0.999$  for each condition). These data show that the extent of PMA-induced morphine desensitization is  $36.5 \pm 2.1\%$ . The extent of decay but not the  $t_{1/2}$  was significantly different in the presence of PMA compared with controls. Similarly when the desensitization kinetics of ME were fitted to single exponential decays, only the maximum extent, but not the  $t_{1/2}$ , were significantly altered by the presence of PMA. The maximum extents and rates of desensitization induced by morphine or ME in the combined presence of PMA and chelerythrine were not significantly different from controls (data not shown).

Further evidence that the enhancing effect of PMA on morphine and ME-induced MOR desensitization was mediated by activation of PKC is that the phorbol ester 4- $\alpha$ -PDD, which does not activate PKC, had no effect on MOR desensitization when ME or morphine were applied (data not shown). We then examined the effects of GF109203X, a bisindolylmaleimide inhibitor of PKC that binds to the active site of the enzyme rather than to the phorbol ester-responsive C1 domain common to a number of phorbol ester-responsive proteins (Yang and Kazanietz, 2003). GF109203X (1  $\mu$ M), like chelerythrine, abolished the enhancement of MOR desensitization by PMA, without affecting the desensitization induced by ME alone (data not shown).

### **M<sub>3</sub> receptor activation enhances morphine desensitization**

LC neurons also express Gq-coupled M<sub>3</sub> muscarinic receptors (Egan and North, 1985). We next tested whether increasing PKC activity by activating M<sub>3</sub> muscarinic receptors can convert morphine into a desensitizing MOR agonist. Addition of the muscarinic agonist oxotremorine-M (oxo-M, 10 μM) resulted in a small inward current ( $77 \pm 11$  pA;  $n = 6$ ) that decayed to a steady level within 10 min ( $57 \pm 12$  pA). When morphine was applied after 10 min of oxo-M treatment, the level of MOR desensitization was dramatically increased (Fig. 2a-c). The facilitatory effect of oxo-M on morphine-induced desensitization was abolished in the presence of the PKC inhibitor, chelerythrine (pre-incubation of 5 μM for 20 min; Fig. 2c), indicating that it resulted from activation of PKC.

We then determined whether the effect of oxo-M on the desensitization induced by ME. ME-induced MOR desensitization was increased by activation of M<sub>3</sub> muscarinic receptors (10 μM oxo-M for 10 min; Fig. 2e,f). The enhancement of desensitization by oxo-M was blocked by pre-incubation of chelerythrine (5 μM; Fig. 1f). No enhancement of spontaneous synaptic events was observed following administration of oxo-M, unlike with PMA.

All desensitization kinetics fitted well to single exponential decays ( $R^2 > 0.999$ ). As with PMA, the maximum extents, but not the rates of morphine or ME-induced desensitization were significantly enhanced by the presence of oxo-M (fig. 2g), an effect that was abolished by the presence of chelerythrine (data not shown).

### **Increased MOR desensitization following PKC activation occurs at the level of the receptor and requires MOR activation**

Other workers have reported that in some cell types (Mao et al., 2004), but not in others (Lesage et al., 1995), PKC has been shown to inhibit GIRK channels. As our functional readout of MOR activation was the opening of GIRKs, it was possible that the apparent increase in MOR desensitization produced by oxo-M or PMA was due to a direct effect of PKC on the channel rather than on the receptor itself. However, we have several pieces of evidence that demonstrate this is not the case, and confirm that the enhancement of MOR desensitization by activation of PKC is mediated at the level of the  $\mu$ -opioid receptor.

Morphine is a partial agonist at MORs in the LC (Bailey et al., 2003). If PKC was acting to inhibit the GIRK channels, then PMA should cause a decrease in the initial peak of the morphine-evoked current. Fig. 3a shows that there was no decrease in the peak of the morphine-evoked current following 20 min PMA application. Also, we performed experiments whereby two brief applications of a submaximal concentration of ME were applied 7 min apart following pre-incubation with PMA for 20 min. Fig. 3b shows that PMA did not reduce the amplitude of the second exposure to ME (second ME response was  $101 \pm 2\%$  of the first,  $n=3$ ), in direct contrast to the enhancement of desensitization seen over the same time scale (see Fig. 1e-f).

To exclude the possibility that PKC activation was in some way producing a use-dependent block of the GIRK channels we made use of the fact that MORs and  $\alpha_2$  adrenoceptors couple to the same set of GIRK channels in LC neurons (North and

Williams, 1985; Bailey and Henderson, unpublished observation). First, we applied noradrenaline (NA; 100  $\mu$ M) before and after ME-induced desensitization. Fig. 3c-d shows that in the presence of PMA the amplitudes of the current evoked by NA before and after ME-induced desensitization were identical in control and PMA-treated slices. Second, we examined the effect of PMA on the rate of desensitization of the noradrenaline-evoked GIRK current. PMA did not significantly enhance the desensitization of the NA-induced response whereas it did enhance the desensitization of the morphine response (Fig 4). Since these two receptors couple to the same set of GIRK channels the enhancement of MOR desensitization by PMA cannot therefore be due to GIRK channel block.

In addition to causing a small inward current, oxo-M also reduced the peak current evoked by both ME and morphine by approximately 40 %. The oxo-M-evoked inward current results from the opening of non-selective cation channels and the closing of GIRK channels (Shen and North, 1992) possibly due to phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) depletion (Huang et al., 1998). An action to close GIRK channels would reduce the MOR current and also, if ongoing during the exposure to morphine, might result in a gradual decay of the morphine-evoked current. However, the oxo-M enhancement of desensitization was reversed by PKC inhibition whereas the reduction of peak morphine- or ME-evoked current in the presence of oxo-M was not reversed by PKC inhibition (data not shown). Thus, oxo-M enhancement of desensitization cannot be due to PIP<sub>2</sub> depletion and subsequent GIRK channel closure, but is mediated by PKC.

## DISCUSSION

There has been much recent controversy concerning the ability of morphine to induced rapid MOR desensitization; a finding that is given rise to new theories concerning the mechanisms underlying morphine tolerance. In LC neurones (Alvarez et al., 2002; Bailey et al., 2003) and HEK 293 cells (Whistler et al., 1999; Finn and Whistler, 2001) morphine has been reported to produce little desensitization of MORs whereas other opioid agonists such as ME, DAMGO and methadone induce significant rapid MOR desensitization. Furthermore, in a number of cell systems, morphine has been shown to cause negligible rapid MOR internalization (Whistler et al., 1999; Finn and Whistler, 2001; Alvarez et al., 2002; Bailey et al., 2003; Borgland et al., 2003; Celver et al., 2004), although a recent study examining trafficking of recombinant MORs in nucleus accumbens neurons showed dendritic redistribution of receptors following morphine (Haberstock-Debic et al., 2003). We now report that in LC neurons, morphine can in fact cause rapid MOR desensitization, but only when PKC is activated. PKC-mediated enhancement of MOR desensitization was evoked in two ways, by directly activating PKC with a phorbol ester (PMA) or indirectly activating PKC through endogenous Gq-coupled M<sub>3</sub> muscarinic receptors. Unlike morphine, ME, in the absence of PKC activation, did induce MOR desensitization. This ME-induced desensitization was not reduced by inhibition of PKC and is likely to be mediated by a G protein receptor kinase (Kovoor et al., 1998; Zhang et al., 1998). Increasing PKC activity with either PMA or an M<sub>3</sub> muscarinic agonist did however enhance ME-induced MOR desensitization (see also Fiorillo and Williams, 1996). The enhancement of morphine- or ME-induced desensitization by PMA or an

M<sub>3</sub> muscarinic agonist was completely reversed by inhibitors of PKC. Indicating that these effects are mediated entirely by PKC activation.

The enhancement of MOR desensitization by PKC activation occurs at the level of the receptor, not at the level of the K<sup>+</sup> channel. This was demonstrated by the fact that the desensitization of  $\alpha_2$  receptors, which are coupled to the same population of GIRK channels, was not significantly enhanced by PMA. Furthermore, the PKC enhancement of desensitization requires agonist activation of the receptor since PMA did not affect the initial amplitude of MOR-evoked currents. We did observe that exposure of slices to PMA resulted in an increase in spontaneous synaptic currents, presumably through a presynaptic action to enhance transmitter release (Malenka et al., 1986). It is possible therefore, that PMA could enhance MOR desensitization indirectly by enhancing the release of various neurotransmitters that subsequently act on the MOR-expressing neuron to somehow increase MOR desensitization. However, we feel that this is unlikely because enhanced transmitter release was not seen following activation of M<sub>3</sub>-muscarinic receptors while PKC-mediated enhanced MOR desensitization was still observed. The ability of PKC to enhance MOR desensitization is unlikely to be mediated by direct phosphorylation of the G-protein as this has been shown, if anything, to enhance the activity of the G $\beta\gamma$  sub-unit (Chakrabarti and Gintzler, 2003).

Although we and others working on LC neurones (Alvarez et al., 2002; Bailey et al., 2003) and HEK-293 cells (Whistler et al., 1999; Finn and Whistler, 2001) have reported that morphine alone does not desensitize MORs, other groups studying MORs transfected into ATt20 cells have found that morphine does induce MOR

desensitization (Borgland et al., 2003; Celver et al., 2004). Whilst at first glance this seems to be a contradiction one possibility is that in ATt20 cells there is a high level of basal PKC activity in this cell-line that is responsible for desensitizing the morphine-activated MOR.

Following 3 day *in vivo* morphine treatments, LC neurons show marked cellular tolerance to morphine (Christie et al., 1987). This study found that the maximum response to morphine was decreased by approximately 40%. This correlates well with our finding of a decrease in maximum response to morphine of 35–37%, in the presence of PMA or oxo-M. As morphine is a partial agonist, this corresponds to approximately 37% loss of functional receptor in the presence of PMA.

MOR desensitization to opioid agonists other than morphine is believed to occur largely by phosphorylation of the activated receptor by GRKs (Kovoor et al., 1998; Zhang et al., 1998) with subsequent binding of arrestins to the phosphorylated receptor uncoupling it from its G proteins (Krupnick and Benovic, 1998). Therefore, PKC activation could enhance agonist-induced MOR desensitization by (i) direct phosphorylation of the receptor, (ii) enhancing the activation of other regulatory proteins such as GRKs, arrestins and MAP kinases, (iii) a combination of both or (iv) by inhibiting receptor recycling and re-activation. Putative consensus sequences for PKC phosphorylation exist on the third intracellular loop and the C terminal tail of the MOR, and PKC has been shown to directly phosphorylate MORs (Zhang et al., 1996), although this was seen even in the absence of opioid agonists, whereas in our experiments agonist activation of the receptor was required before PKC-enhancement of desensitization was observed. Therefore, any PKC phosphorylation

of the MOR in the absence of an opioid agonist in itself does not cause desensitization of the receptor, but may permit some other interaction to take place (e.g. arrestin binding) once the agonist is bound. The specific GRK isoforms most heavily implicated in MOR desensitization are GRK2 and GRK3 (Kovoor et al., 1998; Zhang et al., 1998). The abilities of GRK2 and GRK3 to phosphorylate MOR are enhanced by PKC, either by direct GRK phosphorylation by PKC, or by inducing translocation of GRK2 to the membrane (Chuang et al., 1995; Winstel et al., 1996; Mandyam et al., 2002; Thakker and Standifer, 2002). Therefore, PKC could enhance agonist-induced MOR desensitization indirectly by increasing the activity of GRKs. Indeed Zhang et al. (1998) showed that morphine could cause MOR desensitization in oocytes only when GRK2 was overexpressed.

In arrestin knock-out mice, morphine tolerance was attenuated (Bohn et al., 2000), suggesting that arrestin-dependent MOR desensitization plays a critical role in morphine tolerance. Arrestin can bind not only to GRK-phosphorylated receptors but also to second messenger kinase-phosphorylated receptors (Kohout and Lefkowitz, 2003). Thus arrestin may bind to and desensitize PKC phosphorylated MORs receptors. Interestingly, the residual component of morphine tolerance present in arrestin knockout mice was removed by administration of a PKC inhibitor (Bohn et al., 2002). Thus PKC may induce MOR desensitization in an arrestin-dependent and an arrestin-independent manner. Indeed, some groups have reported that the regulation of GPCR-mediated signalling by PKC and arrestin are separable phenomena (Krupnick and Benovic, 1998).



A further potential explanation for our findings is that PKC may inhibit MOR trafficking, reinsertion, and therefore resensitization. Indeed Ueda et al. (2001) demonstrated that inhibition of PKC could cause enhanced morphine-bound MOR internalization and reinsertion in Chinese hamster ovary cells. However, a recent study (Dang and Williams, 2004) showed that PKC inhibition attenuated the rate of recovery from ME-induced desensitization. Therefore, if anything, PKC activation may increase receptor resensitization in these neurons.

The original observation that morphine caused very little rapid MOR desensitization (Whistler et al., 1999) led to the suggestion that morphine tolerance occurs, not because of receptor desensitization, but precisely because the lack of MOR desensitization gives rise to prolonged signalling from the morphine-activated MOR and this results in the development of other compensatory cellular changes that act to diminish that signalling and thus result in the development of tolerance (Finn and Whistler, 2001). Our data demonstrate that morphine can indeed cause significant rapid MOR desensitization in adult rat LC neurons, when PKC is activated. We would suggest that PKC may therefore be involved in the development of morphine tolerance. In the intact nervous system there is likely to be ongoing activation of Gq-coupled receptors, thus the levels of PKC activity within individual neurons are likely to be raised, in comparison to quiescent neurons in brain slices. Therefore, *in vivo*, G-protein coupled receptor crosstalk between the MOR and Gq-coupled receptors and enhanced PKC activity may play significant roles in morphine-induced desensitization of MORs and thus be responsible for the development of morphine tolerance.

Evidence to support our hypothesis comes from behavioural studies showing that morphine tolerance can be reduced by PKC inhibitors (e.g., Granados-Soto et al., 2000; Inoue and Ueda, 2000; Bohn et al., 2002; Hua et al., 2002), in PKC knockout mice (Zeitz et al., 2001), or by blockade of various Gq-coupled receptors (e.g., Watkins et al., 1984; Popik et al., 2000; Powell et al., 2003), or can be enhanced by activation of PKC (Narita et al., 1997). In addition, NMDA receptor antagonism has been shown to reduce morphine tolerance (Trujillo and Akil, 1991). NMDA receptor activation would result in calcium influx and thus PKC activation (Mao et al., 1995). Indeed, the facilitatory effect of PKC on morphine-induced rapid MOR desensitization can also contribute to acute morphine tolerance seen during a single dose (Watkins et al., 1984; Bohn et al., 1999), meaning that agents which inhibit PKC can be used clinically as adjuncts to morphine (Caruso, 2000).

## REFERENCES

Alvarez VA, Arttamangkul S, Dang V, Salem A, Whistler JL, von Zastrow M, Grandy DK, Williams JT (2002) Mu-Opioid receptors: Ligand-dependent activation of potassium conductance, desensitization, and internalization. *J Neurosci* 22:5769-5776.

Bailey CP, Couch D, Johnson E, Griffiths K, Kelly E, Henderson G (2003) Mu-opioid receptor desensitization in mature rat neurons: lack of interaction between DAMGO and morphine. *J Neurosci* 23:10515-10520.

Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin F-T (1999) Enhanced morphine analgesia in mice lacking beta-arrestin 2. *Science* 286:2495-2498.

Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG (2000) Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. *Nature* 408:720-723.

Bohn LM, Lefkowitz RJ, Caron MG (2002) Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. *J Neurosci* 22:10494-1050.

Borgland SL, Connor M, Osborne PB, Furness JB, Christie MJ (2003) Opioid agonists have different efficacy profiles for G protein activation, rapid

desensitization, and endocytosis of mu-opioid receptors. *J Biol Chem* 278:18776-18784.

Caruso FS (2000) MorphiDex pharmacokinetic studies and single-dose analgesic efficacy studies in patients with postoperative pain. *J Pain Symptom Manage* 19:S31-36.

Celver J, Xu M, Jin W, Lowe J, Chavkin C (2004) Distinct domains of the mu-opioid receptor control uncoupling and internalization. *Mol Pharmacol* 65:528-537.

Chakrabarti S, Gintzler AR (2003) Phosphorylation of Gbeta is augmented by chronic morphine and enhances Gbetagamma stimulation of adenylyl cyclase activity. *Mol Brain Res* 119:144-151.

Christie MJ, Williams JT, North RA (1987) Cellular mechanisms of opioid tolerance: studies in single brain neurons. *Mol Pharmacol* 32:633-638.

Chuang TT, LeVine H III, De Blasi A (1995) Phosphorylation and activation of beta-adrenergic receptor kinase by protein kinase C. *J Biol Chem* 270:18660-18665.

Dang VC, Williams JT (2004) Chronic morphine treatment reduces recovery from opioid desensitization. *J Neurosci* in press.

Egan TM, North RA (1985) Acetylcholine acts on M2-muscarinic receptors to excite rat locus coeruleus neurones. *Br J Pharmacol* 85:733-735.

Finn AK, Whistler JL (2001) Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. *Neuron* 32:829-839.

Fiorillo CD, Williams JT (1996) Opioid desensitization: interactions with G-protein-coupled receptors in the locus coeruleus. *J Neurosci* 16:1479-1485.

Granados-Soto V, Kalcheva I, Hua X-Y, Newton A, Yaksh TL (2000) Spinal PKC activity and expression: role in tolerance produced by continuous spinal morphine infusion. *Pain* 85:395-404.

Haberstock-Debic H, Wein M, Barrot M, Colago EEO, Rahman Z, Neve RL, Pickel VM, Nestler EJ, von Zastrow M, Svingos AL (2003) Morphine acutely regulates opioid receptor trafficking selectively in dendrites of nucleus accumbens neurons. *J Neurosci* 23:4324-4332.

Hua XY, Moore A, Malkmus S, Murray SF, Dean N, Yaksh TL, Butler M (2002) Inhibition of spinal protein kinase Calpha expression by an antisense oligonucleotide attenuates morphine infusion-induced tolerance. *Neuroscience* 113:99-107.

Huang CL, Feng S, Hilgemann DW (1998) Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by Gbetagamma. *Nature* 391:803-806.

Inoue M, Ueda H (2000) Protein kinase C-mediated acute tolerance to peripheral mu-opioid analgesia in the bradykinin-nociception test in mice. *J Pharmac Exp Ther* 293:662-669.

Kohout TA, Lefkowitz RJ (2003) Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. *Mol Pharmacol* 63:9-18.

Kovoor A, Celver JP, Wu A, Chavkin C (1998) Agonist induced homologous desensitization of mu-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy. *Mol Pharmacol* 54:704-711.

Krupnick JG, Benovic JL (1998) The role of receptor kinases and arrestins in G protein-coupled receptor regulation. *Annu Rev Pharmacol Toxicol* 38:289-319.

Lesage F, Guillemare E, Fink M, Duprat F, Heurteaux C, Fosset M, Romey G, Barhanin J, Lazdunski M (1995) Molecular properties of neuronal G-protein-activated inwardly rectifying K<sup>+</sup> channels. *J Biol Chem* 270:28660-28667.

Liu J-G, Anand KJS (2001) Protein kinases modulate the cellular adaptations associated with tolerance and dependence. *Brain Res Rev* 38:1-19.

Malenka RC, Madison DV, Nicoll RA (1986) Potentiation of synaptic transmission in the hippocampus by phorbol esters. *Nature* 321:175-177.

Mandyam CD, Thakker DR, Christensen JL, Standifer KM (2002) Orphanin FQ/nociceptin-mediated desensitization of opioid receptor-like 1 receptor and  $\mu$  opioid receptors involves protein kinase C: a molecular mechanism for heterologous cross-talk. *J Pharm Exp Ther* 302:502-509.

Mao J, Price DD, Mayer DJ (1995) Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. *Pain* 62:259-274.

Mao J, Wang X, Chen F, Wang R, Rojas A, Shi Y, Piao H, Jiang C (2004) Molecular basis for the inhibition of G protein-coupled inward rectifier K(+) channels by protein kinase C. *Proc Natl Acad Sci USA* 101:1087-1092.

Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P et al Tzavara E, Hanoune J, Roques BP, Kieffer BL (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. *Nature* 383:819-823.

Narita M, Ohsawa M, Mizoguchi H, Kamei J, Tseng LF (1997) Pretreatment with protein kinase C activator phorbol 12,13-dibutyrate attenuates the antinociception induced by  $\mu$ - but not  $\epsilon$ -opioid receptor agonist in the mouse. *Neuroscience* 76:291-298.

Nestler EJ, Aghajanian GK (1997) Molecular and cellular basis of addiction. *Science* 278:58-62.

North RA, Williams JT (1985) On the potassium conductance increased by opioids in rat locus coeruleus neurones. *J Physiol* 364:265-280.

North RA, Williams JT, Surprenant A, Christie MJ (1987) Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. *Proc Natl Acad Sci USA* 84:5487-5491.

Popik P, Kozela E, Pilc A (2000) Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice. *Br J Pharmacol* 130:1425-1431.

Powell KJ, Quirion R, Jhamandas K (2003) Inhibition of neurokinin-1-substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons. *Eur J Neurosci* 18:1572-1583.

Shen KZ, North RA (1992) Muscarine increases cation conductance and decreases potassium conductance in rat locus coeruleus neurones. *J Physiol* 455:471-485.

Thakker DR, Standifer KM (2002) Induction of G protein-coupled receptor kinases 2 and 3 contributes to the cross-talk between  $\mu$  and ORL1 receptors following prolonged agonist exposure. *Neuropharmacology* 43:979-990.

Trujillo KA, Akil H (1991) Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. *Science* 251:85-87.



Ueda H, Inoue M, Matsumoto T (2001) Protein kinase C-mediated inhibition of  $\mu$ -opioid receptor internalization and its involvement in the development of acute tolerance to peripheral  $\mu$ -agonist analgesia. *J Neurosci* 21:2967-2973.

Watkins LR, Kinscheck IB, Mayer DJ (1984) Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. *Science* 224:395-396.

Whistler JL, Chuang HH, Chu P, Jan LY, von Zastrow M (1999) Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. *Neuron* 23:737-746.

Winstel R, Freund S, Krasel C, Hoppe E, Lohse MJ (1996) Protein kinase cross-talk: membrane targeting of the beta-adrenergic receptor kinase by protein kinase C. *Proc Natl Acad Sci USA* 93:2105-2109.

Yang C and Kazanietz MG (2003) Divergence and complexities in DAG signaling: looking beyond PKC. *Trends Pharmacol Sci* 24:602-608.

Zeitl KP, Malmberg AB, Gilbert H, Basbaum AI (2001) Reduced development of tolerance to the analgesic effects of morphine and clonidine in PKC gamma mutant mice. *Pain* 102:245-253.

Zhang L, Yu Y, Mackin S, Weight FF, Uhl GR, Wang JB (1996) Differential mu opiate receptor phosphorylation and desensitization induced by agonists and phorbol esters. *J Biol Chem* 271:11449-11454.

Zhang J, Ferguson SS, Barak LS, Bodduluri SR, Laporte SA, Law PY, Caron MG (1998) Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. *Proc Natl Acad Sci USA* 95:7157-7162.

## FOOTNOTES

Financial support provided by the Wellcome Trust.

Name and address for reprint requests:

Dr. C. P. Bailey, Department of Pharmacology, University of Bristol, Medical School, University Walk, Bristol, BS8 1TD, United Kingdom. Email: Chris.Bailey@bris.ac.uk

## FIGURE LEGENDS

### Figure 1

#### Direct activation of PKC by a phorbol ester enhances MOR desensitization.

(a & b) In the presence of PMA (1  $\mu$ M) morphine (30  $\mu$ M) caused MOR desensitization. Drugs were applied for the durations indicated by the bars. Each trace is from a separate cell. Scale bars represent 50 pA, 5 min. (c) Superimposed traces, scaled to give equal peak responses, evoked by morphine in the absence (black) and presence (grey) of PMA. Scale bar represents = 5 min. (d) Pooled data (n = 4-12) showing the time-course of morphine-induced desensitization in control cells (black squares) and in cells exposed to PMA (open circles; \* P < 0.01 vs. control). The effect of PMA was inhibited by chelerythrine (5  $\mu$ M; black triangles; † P < 0.01 vs. PMA alone). (e) ME-induced desensitization was increased after PMA incubation (grey trace, in the presence of PMA; control, black trace; scale bar represents 5 min). (f) Pooled data showing ME-induced desensitization in control slices (black squares) in the presence of PMA (open circles) and in the presence of PMA + chelerythrine (black triangles; n = 4-14; \* P < 0.01 vs. control; † P < 0.01 vs. PMA alone). (g) Desensitization kinetics of data displayed in fig. 1b and 1d. All data from a single treatment group were pooled and a single line of best-fit was constructed from a single exponential decay (all lines of best-fit  $R^2 > 0.999$ ). Maximum desensitization (%) was obtained from the plateau of the line of best-fit and are displayed as mean  $\pm$  standard error of the mean.  $T_{1/2}$  values for decay (in seconds) are displayed as means with 95% confidence intervals in parentheses. \* P < 0.01 vs. morphine alone; † P < 0.01 vs. ME alone; Student's t-test. (h & i) Administration of chelerythrine (5  $\mu$ M) alone had no effect on agonist-induced MOR desensitization. Pooled data from 3-12

cells (**h**) showing no effect of chelerythrine (open circles) on morphine-induced MOR desensitization; control (black squares). Similarly chelerythrine did not affect ME-induced MOR desensitisation (**i**: control, black squares; + chelerythrine, open circles). All data were analysed by two-way ANOVA.

## Figure 2

### MOR desensitization in LC neurons is enhanced by M<sub>3</sub> muscarinic receptor activation.

(**a & b**) Morphine-evoked currents in single LC neurons. Morphine (30  $\mu$ M) alone caused little MOR desensitization. In the presence of oxo-M (10  $\mu$ M) morphine induced a current that showed significant desensitization. Oxo-M was present for 10 mins prior to, and during, morphine application. The oxo-M-induced current had declined to steady state before morphine application. (**c**) Pooled data from 4-12 cells showing the time-course of morphine-induced desensitization in control (black squares) and oxo-M-treated (open circles) cells; \*  $P < 0.01$  vs. control. The effect of oxo-M was inhibited by the PKC inhibitor, chelerythrine (5  $\mu$ M; black triangles;  $n = 3$ ; †  $P < 0.01$  vs. oxo-M alone). (**d & e**) In control cells the current evoked by ME (30  $\mu$ M) rapidly desensitized. Pre-exposure to oxo-M (10  $\mu$ M for 10 min) increased the ME-induced desensitization. (**f**) Pooled data from 3-14 cells showing the time-course of the oxo-M enhancement (open circles) of the ME-induced desensitization (black squares), an effect that was inhibited by chelerythrine (5  $\mu$ M; black triangles;  $n = 4$ ; \*  $P < 0.01$  vs. control; †  $P < 0.01$  vs. oxo-M alone). For current traces, scale bars represent 50 pA and 5 min. All data were analysed by two-way ANOVA. (**g**) Desensitization kinetics of fig. 2c and 2f, analyzed as in fig. 1g. All lines of best-fit  $R^2 > 0.999$ . \*  $P < 0.01$  vs. morphine alone; †  $P < 0.01$  vs. ME alone; Student's t-test.

### Figure 3

#### Activation of PKC increases MOR desensitization at the level of the receptor.

(a) The peak current evoked by morphine (30  $\mu$ M), expressed as a percentage of maximal MOR current (derived by application of 10  $\mu$ M ME) was unaffected by 20 min preincubation of PMA (1  $\mu$ M). Grey bar, control; white bar in the presence of PMA (n = 5). (b) Responses to brief applications of ME (1  $\mu$ M) in the presence of PMA (1  $\mu$ M) did not decrease. This sample trace is typical of 3 experiments in the presence of PMA in which the second response was  $101 \pm 2\%$  of the first. Scale bars represent 50 pA and 5 min. (c & d) NA current amplitude was unaffected by PMA (1  $\mu$ M), or by PMA-enhanced 30  $\mu$ M ME-induced MOR desensitization. Scale bars represent 50 pA and 5 min. (d) Pooled data (n = 5 – 12 cells) showing the NA current amplitude after ME-induced MOR desensitization as a percentage of the initial NA response. Con, control; + PMA, in the presence of 1  $\mu$ M PMA.

### Figure 4

#### Activation of PKC does not increase NA-induced desensitization of $\alpha_2$ receptors.

(a) A saturating concentration of NA (100  $\mu$ M) caused a small degree of desensitization over the course of a 7 min exposure to the drug. The level of desensitization was not increased in the presence of PMA (1  $\mu$ M). Sample traces, scale bars represent 50 pA and 5 min. (b) Traces shown in (a) scaled and superimposed. Black trace control; grey trace = + PMA. Scale bar 5 min. (c) Pooled data from 5-11 cells show that slices incubated with PMA (white circles) exhibit a similar degree of NA-induced desensitization to control cells (black squares). (d)

PMA increased morphine-induced MOR desensitization, measured after 7 min of drug exposure, to a significantly greater extent than noradrenaline-induced  $\alpha_2$  adrenoceptor desensitization. Columns represent the percent enhancement of desensitization after 7 min of drug exposure to morphine (30  $\mu$ M) or noradrenaline (NA; 100  $\mu$ M) in the presence of PMA (1  $\mu$ M). (n = 5, \* P < 0.05 morphine vs. NA; Student's t-test).




Figure 1






Figure 2




Figure 3




Figure 4